Page 2 - Pharma Industry
Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth
2.4 mg injectable Poviztra to mark next phase of weight-loss rollout
 "Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth")
Pharma units likely to face action for Schedule M violations: Experts
The one-year grace period for MSME drug manufacturers to comply with revised Schedule M norms has ended, with the CDSCO instructing state regulators to initiate inspections & action against violators
 "Pharma units likely to face action for Schedule M violations: Experts")
Mounjaro India's bestselling drug in October with ₹100 crore sales
Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind
 "Mounjaro India's bestselling drug in October with ₹100 crore sales")
Rebound in US biopharma funding may boost orders, says Piramal Pharma
The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26
 "Rebound in US biopharma funding may boost orders, says Piramal Pharma")
Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%
Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.
 "Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%")
NPPA fixes retail price of 28 drugs, ceiling price of six formulations
The National Pharmaceutical Pricing Authority has revised retail prices of 28 formulations and capped ceiling prices for six drugs under the National List of Essential Medicines
 "NPPA fixes retail price of 28 drugs, ceiling price of six formulations")
Lupin Q2 PAT rises 73% on strong growth across key global markets
Lupin's consolidated profit rose 73% YoY to Rs 1,478 crore in Q2 FY26, led by robust sales in India and the US and higher margins from an improved product mix
 "Lupin Q2 PAT rises 73% on strong growth across key global markets")
Alembic Pharma Q2 profit rises 21% on robust US generics and API growth
Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals
 "Alembic Pharma Q2 profit rises 21% on robust US generics and API growth")
Gland Pharma Q2 results: Profit rises 12% on recovery at Europe's Cenexi
The consolidated net profit rose to 1.84 billion rupees (nearly $21 million) for the quarter ended September 30 from 1.64 billion rupees a year earlier
Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026
Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016
 "Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026")
Centre brings draft rules to debar drugmakers who provide fake information
The health ministry proposes new provisions under the Drugs Rules, 1945, allowing regulators to bar applicants who submit fake or misleading data for approvals
 "Centre brings draft rules to debar drugmakers who provide fake information")
Cough syrup deaths: CDSCO launches digital tracker for high-risk solvents
The regulator's ONDLS-based monitoring platform will track supply chains and quality of solvents used in drug manufacturing following child deaths linked to toxic cough syrups
 "Cough syrup deaths: CDSCO launches digital tracker for high-risk solvents")
Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.
The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio
 "Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.")
Lilly and Cipla to market tirzepatide in India under new brand Yurpeak
The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets
 "Lilly and Cipla to market tirzepatide in India under new brand Yurpeak")
Results preview: Pharma sales may be up 9-10% in Q2 on robust domestic biz
Domestic business and exports are expected to be a shot in the arm; hospitals and diagnostics to lag
 "Results preview: Pharma sales may be up 9-10% in Q2 on robust domestic biz")
Risdiplam generic drug case: SC rejects Roche plea against Natco pharma
The Supreme Court upheld Delhi HC's interim order allowing Natco Pharma to manufacture and sell a generic version of Roche's spinal muscular atrophy drug Risdiplam
 "Risdiplam generic drug case: SC rejects Roche plea against Natco pharma")
Centre refuses deadline extension for pharma firms after Coldrif deaths
The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities
 "Centre refuses deadline extension for pharma firms after Coldrif deaths")
India's pharma regulatory failures point to a deeper structural flaw
These are not independent, random occurrences. They are all pointers to a larger, more fundamental issue
 "India's pharma regulatory failures point to a deeper structural flaw")
Datanomics: Surge in substandard drugs raises safety concerns in India
India faced global scrutiny in 2023 when its cough syrups were linked to the deaths of dozens of children in Gambia
Indian pharma market grows 7.3% in September, chronic drugs gain traction
India's pharmaceutical market rose 7.3% year-on-year in September to ₹20,886 crore, driven by robust growth in antidiabetic, cardiac, and respiratory therapies